Category: Press Release - Page 29 - Psychedelic Alpha

Read more about the article PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX™ (Ketamine) On-Body Pump System

PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX™ (Ketamine) On-Body Pump System

Post published:February 7, 2023
Post category:Press Release

Read more about the article Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development

Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development

Post published:February 6, 2023
Post category:Press Release

Read more about the article Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL

Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL

Post published:February 6, 2023
Post category:Press Release

Read more about the article Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch

Post published:February 3, 2023
Post category:Press Release

Read more about the article PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome

PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome

Post published:February 2, 2023
Post category:Press Release

Read more about the article Silo Pharma Announces Expansion of Intellectual Property Portfolio

Silo Pharma Announces Expansion of Intellectual Property Portfolio

Post published:February 2, 2023
Post category:Press Release

Read more about the article Ehave Provides Progress Update on its HPPD Study with University of Melbourne

Ehave Provides Progress Update on its HPPD Study with University of Melbourne

Post published:February 2, 2023
Post category:Press Release

Read more about the article Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET

Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET

Post published:February 2, 2023
Post category:Press Release

Read more about the article Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs

Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs

Post published:February 2, 2023
Post category:Press Release

Read more about the article PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson’s Disease

PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson’s Disease

Post published:February 1, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.